Cumberland Pharmaceuticals (CPIX) Competitors $1.12 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CPIX vs. REPH, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, RPRX, and JAZZShould you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Recro Pharma (REPH), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), and Jazz Pharmaceuticals (JAZZ). Cumberland Pharmaceuticals vs. Recro Pharma Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Royalty Pharma Jazz Pharmaceuticals Recro Pharma (NASDAQ:REPH) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability. Do insiders and institutionals believe in REPH or CPIX? 62.3% of Recro Pharma shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 14.2% of Recro Pharma shares are held by insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to REPH or CPIX? In the previous week, Cumberland Pharmaceuticals had 34 more articles in the media than Recro Pharma. MarketBeat recorded 34 mentions for Cumberland Pharmaceuticals and 0 mentions for Recro Pharma. Recro Pharma's average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.20 indicating that Recro Pharma is being referred to more favorably in the media. Company Overall Sentiment Recro Pharma Neutral Cumberland Pharmaceuticals Neutral Which has stronger valuation & earnings, REPH or CPIX? Cumberland Pharmaceuticals has lower revenue, but higher earnings than Recro Pharma. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecro Pharma$75.36M0.00-$11.37M-$0.31N/ACumberland Pharmaceuticals$39.55M0.40-$6.28M-$0.73-1.53 Do analysts prefer REPH or CPIX? Given Recro Pharma's higher probable upside, analysts plainly believe Recro Pharma is more favorable than Cumberland Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recro Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACumberland Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has more volatility and risk, REPH or CPIX? Recro Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Does the MarketBeat Community prefer REPH or CPIX? Recro Pharma received 162 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 54.45% of users gave Recro Pharma an outperform vote while only 42.79% of users gave Cumberland Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRecro PharmaOutperform Votes34954.45% Underperform Votes29245.55% Cumberland PharmaceuticalsOutperform Votes18742.79% Underperform Votes25057.21% Is REPH or CPIX more profitable? Recro Pharma has a net margin of -15.15% compared to Cumberland Pharmaceuticals' net margin of -27.45%. Cumberland Pharmaceuticals' return on equity of -6.86% beat Recro Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Recro Pharma-15.15% -56.66% -11.14% Cumberland Pharmaceuticals -27.45%-6.86%-2.46% SummaryRecro Pharma beats Cumberland Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Cumberland Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPIX vs. The Competition Export to ExcelMetricCumberland PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.79M$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-1.539.47113.8115.12Price / Sales0.40381.571,483.2593.03Price / Cash1.7247.3339.6434.05Price / Book0.575.324.665.02Net Income-$6.28M$153.56M$119.06M$225.46M7 Day Performance-8.20%0.12%0.79%0.37%1 Month Performance-9.68%15.23%5.65%3.57%1 Year Performance-44.00%41.16%36.76%29.42% Cumberland Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPIXCumberland Pharmaceuticals0.5882 of 5 stars$1.12flatN/A-37.1%$15.79M$39.55M-1.5380Upcoming EarningsAnalyst ForecastREPHRecro PharmaN/AN/AN/AN/A$117.93M$75.36M-6.74185Analyst ForecastLLYEli Lilly and Company4.9055 of 5 stars$903.34+0.9%$1,013.41+12.2%+47.7%$858.54B$38.92B111.2543,000Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionJNJJohnson & Johnson4.8841 of 5 stars$161.01-0.4%$175.93+9.3%+7.7%$387.50B$87.70B23.30131,900Short Interest ↓ABBVAbbVie4.8525 of 5 stars$189.43-0.1%$199.39+5.3%+42.9%$334.51B$55B63.1450,000Earnings ReportDividend IncreaseAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageMRKMerck & Co., Inc.4.9993 of 5 stars$104.17-0.1%$131.46+26.2%-1.0%$263.84B$60.12B19.3372,000Earnings ReportAnalyst ForecastNews CoveragePFEPfizer4.9876 of 5 stars$28.31-1.9%$33.58+18.6%-8.0%$160.42B$58.50B-61.5488,000Earnings ReportAnalyst UpgradeAnalyst RevisionBMYBristol-Myers Squibb4.5171 of 5 stars$52.49-0.3%$53.57+2.1%+6.0%$106.40B$46.51B-16.1034,100Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageZTSZoetis4.9089 of 5 stars$182.21-0.3%$221.44+21.5%+20.1%$82.55B$8.92B35.6614,100Upcoming EarningsRPRXRoyalty Pharma4.7657 of 5 stars$27.10-0.6%$41.67+53.8%-0.5%$16.19B$2.24B23.9880Upcoming EarningsJAZZJazz Pharmaceuticals4.7869 of 5 stars$112.04+0.6%$173.43+54.8%-13.3%$7.07B$3.91B19.252,800Upcoming Earnings Related Companies and Tools Related Companies REPH Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives ZTS Alternatives RPRX Alternatives JAZZ Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CPIX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
